Xiamen Amoytop Biotech Co., Ltd.

This early-stage trial is testing a new drug called ACT500 in 24 people who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will take ACT500 or a placebo daily, and r…

This early-stage study tests a new oral drug called ACT500 in 24 adults with fatty liver disease (MASLD). The main goal is to check safety and how the drug moves through the body. Participants take one pill daily in different dose groups. The study does not aim to cure the diseas…

This early-stage study will test the safety and tolerability of a new drug called ACT100 in 48 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. This is the first …